This unique monoclonal protein, Pritoxaximab – formerly known as DXX00601 – shows significant opportunity for the treatment of severe hemolytic disease (TRALI). Engineered by Bio-X, Pritoxaximab works by inhibiting https://bookmark-dofollow.com/story29647849/pritoxaximab-a-deep-dive-into-dxx00601-s-potential